Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NXTC 
NextCure Inc (NXTC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: NXTC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $17.5
1 Year Target Price $17.5
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -57.27% | Avg. Invested days 18 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.16M USD | Price to earnings Ratio - | 1Y Target Price 17.5 |
Price to earnings Ratio - | 1Y Target Price 17.5 | ||
Volume (30-day avg) 2 | Beta 1.27 | 52 Weeks Range 2.69 - 19.20 | Updated Date 09/17/2025 |
52 Weeks Range 2.69 - 19.20 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -25.97 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -53.12% | Return on Equity (TTM) -105.88% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -15923395 | Price to Sales(TTM) 9.52 |
Enterprise Value -15923395 | Price to Sales(TTM) 9.52 | ||
Enterprise Value to Revenue 1.62 | Enterprise Value to EBITDA 0.51 | Shares Outstanding 2676110 | Shares Floating 1878843 |
Shares Outstanding 2676110 | Shares Floating 1878843 | ||
Percent Insiders 14.79 | Percent Institutions 32.58 |
Upturn AI SWOT
NextCure Inc
Company Overview
History and Background
NextCure, Inc. is a biopharmaceutical company focused on discovering and developing immunomedicines to treat cancer. Founded in 2015, it leverages its FIND-IO platform to discover and validate novel targets and develop therapies that modulate the immune system to fight cancer. The company has progressed from initial target discovery to clinical trials.
Core Business Areas
- Research and Development: Focuses on discovering and developing new immunotherapies based on the FIND-IO platform.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Partnerships and Licensing: Collaborates with other pharmaceutical companies to advance the development and commercialization of its products.
Leadership and Structure
Michael Richman serves as the President and CEO. The company has a management team and board of directors with expertise in oncology, immunology, and drug development.
Top Products and Market Share
Key Offerings
- NC410: NC410 is a LAIR-1 antagonist antibody being developed for the treatment of solid tumors. Market share data is unavailable as it is in clinical development. Competitors in immuno-oncology include Merck (Keytruda), Bristol Myers Squibb (Opdivo), and Roche (Tecentriq), though their specific mechanisms of action differ.
- NC762: NC762 is a B7-H4 antagonist antibody being developed for the treatment of solid tumors. Market share data is unavailable as it is in clinical development. Competitors include companies developing therapies targeting similar immune checkpoints, but B7-H4 is a relatively novel target.
Market Dynamics
Industry Overview
The immuno-oncology market is experiencing substantial growth, driven by the success of checkpoint inhibitors and the increasing understanding of the immune system's role in cancer. Innovation is focused on novel targets and combination therapies.
Positioning
NextCure is positioned as an innovative player in the immuno-oncology field, focusing on discovering and developing novel targets using its proprietary FIND-IO platform. Its competitive advantage lies in its unique target discovery approach.
Total Addressable Market (TAM)
The global immuno-oncology market is projected to reach hundreds of billions of USD by the end of the decade. NextCure is positioned to capture a portion of this market by focusing on novel targets and unmet needs.
Upturn SWOT Analysis
Strengths
- Proprietary FIND-IO platform for novel target discovery
- Strong focus on immuno-oncology
- Experienced management team
- Innovative pipeline with differentiated assets
Weaknesses
- Early-stage clinical development
- High cash burn rate
- Reliance on partnerships for development and commercialization
- Lack of approved products
Opportunities
- Positive clinical trial results could lead to significant valuation increase
- Potential for partnerships and licensing deals
- Expansion into new cancer indications
- Advancements in understanding of immuno-oncology
Threats
- Clinical trial failures
- Competition from established players
- Regulatory hurdles
- Funding challenges
Competitors and Market Share
Key Competitors
- MRK
- BMY
- RHHBY
Competitive Landscape
NextCure faces intense competition from established pharmaceutical companies. Its advantage lies in its novel target discovery platform, but it needs to demonstrate clinical efficacy to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily focused on advancing its drug candidates through preclinical and clinical development stages.
Future Projections: Future growth is dependent on the success of its clinical trials and potential partnerships. Analyst estimates are unavailable without a live data feed.
Recent Initiatives: Recent initiatives include advancing clinical trials for NC410 and NC762, and exploring new targets through the FIND-IO platform.
Summary
NextCure is a preclinical stage immuno-oncology company that uses a novel approach to discover new drug targets and is in early stages of clinical trials. The company has a platform technology that could lead to valuable new therapies. The company's financials are limited due to early-stage development, and therefore it faces strong competition from companies with approved drugs. It must successfully navigate clinical trials and secure partnerships to generate future value and reduce the cash burn rate.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share estimates are approximate and based on publicly available information. Forward-looking statements are subject to risks and uncertainties.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NextCure Inc
Exchange NASDAQ | Headquaters Beltsville, MD, United States | ||
IPO Launch date 2019-05-09 | Co-Founder, CEO, President & Director Mr. Michael S. Richman MSBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 43 | Website https://www.nextcure.com |
Full time employees 43 | Website https://www.nextcure.com | ||
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.